Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imatinib + chemotherapy
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral (imatinib), Intravenous, Oral, Others (chemotherapy, Depending On The Agent)
01
Overview
**Imatinib + chemotherapy** is not a single fixed-dose combination drug but refers to the administration of **imatinib** (a small molecule tyrosine kinase inhibitor) alongside one or more chemotherapeutic agents. Imatinib inhibits the BCR-ABL fusion protein, which drives the proliferation of cells in chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). "Chemotherapy" in this context refers to cytotoxic drugs commonly used in cancer treatment (such as doxorubicin, cytarabine, cyclophosphamide, vincristine, and others), which act primarily by interfering with DNA replication or cellular metabolism, broadly targeting rapidly dividing cells. The combination is sometimes used experimentally or in advanced/metastatic settings, such as for CML, certain gastrointestinal stromal tumors (GIST), and other BCR-ABL-positive leukemias or solid tumors, to improve outcomes or overcome resistance to single-agent therapy[2][3].
- Brand names
- GleevecGlivec
- Other names
- imatinib mesylate + chemotherapy
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)PDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNA
Beyond the preview
Go deeper on imatinib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imatinib + chemotherapy.